Podcasts Health & Fitness Medicine NEJM Interviews NEJM Interview: Dr. Elliot Israel on the risks and benefits of long-acting beta agonists in the treatment of asthma and COPD.

NEJM Interview: Dr. Elliot Israel on the risks and benefits of long-acting beta agonists in the treatment of asthma and COPD.

Published: Dec. 14, 2011, 3:01 p.m.

b"Dr. Elliot Israel is a Professor of Medicine at Harvard Medical School and the Director of Clinical Research in the Pulmonary and Critical Care Division at Brigham and Women's Hospital, both in Boston. Stephen Morrissey, the interviewer, is the Managing Editor of the Journal. Supplement to: Chowdhury B et al. The Risks and Benefits of Indracaterol - The FDA's Review. N Engl J Med 2011;365:2247-9."